Lista de obras - Maria Di Bartolomeo - Dominio Público Uruguay

A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer

artículo científico publicado en 2011

A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer

artículo científico publicado en 2015

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

artículo científico publicado en 2013

Adjuvant chemotherapy for gastric cancer: current evidence and future challenges.

artículo científico publicado en 2014

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

artículo científico publicado en 2019

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

artículo científico publicado en 2015

BRAF in metastatic colorectal cancer: the future starts now.

artículo científico publicado en 2015

Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen

artículo científico publicado en 2012

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

artículo científico publicado en 2015

Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians.

artículo científico

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer

artículo científico publicado en 2007

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

article

Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study11Data management by Italian Trials in Medical Oncology (I.T.M.O.) Scientific Service

article

Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies

artículo científico publicado en 2014

Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer

artículo científico publicado en 2014

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens

artículo científico publicado en 2014

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.

artículo científico publicado en 2015

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

scientific article published on 01 January 1996

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology

artículo científico publicado en 1995

Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials

artículo científico publicado en 2015

Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression

artículo científico publicado en 1994

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

artículo científico publicado en 2015

Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients

artículo científico publicado en 2008

Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer

artículo científico publicado en 2015

Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens

artículo científico publicado en 1997

Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis

artículo científico

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours

artículo científico publicado en 2002

Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients

artículo científico publicado en 2004

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

artículo científico publicado en 1995

Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma

scientific article published on 01 January 1993

Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group

artículo científico publicado en 1994

FOLFIRI with cetuximab or bevacizumab: FIRE-3

scientific article published on 24 November 2014

FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma

artículo científico publicado en 2014

Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial

artículo científico publicado en 2006

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

artículo científico publicado en 2015

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

artículo científico publicado en 2016

Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status

artículo científico publicado en 2014

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

artículo científico publicado en 2016

Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.

artículo científico publicado en 2012

Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer

artículo científico publicado en 2016

Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials

artículo científico publicado en 2014

Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?

artículo científico publicado en 2013

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.

artículo científico publicado en 2012

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

artículo científico publicado en 2013

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

artículo científico publicado en 2016

Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer

artículo científico publicado en 1995

Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.

artículo científico publicado en 2015

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

artículo científico publicado en 2008

Pathological features as predictors of recurrence after radical resection of gastric cancer

scientific article published on 01 February 2006

Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases

article

Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases

artículo científico publicado en 2016

Phase II Study of the Etoposide, Leucovorin and Fluorouracil Combination for Patients with Advanced Gastric Cancer Unsuitable for Aggressive Chemotherapy

artículo científico publicado en 1995

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

artículo científico publicado en 2015

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

artículo científico publicado en 2018

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

artículo científico publicado en 2004

Resection versus transplantation for liver metastases from neuroendocrine tumors

scientific article published on 01 February 2001

Role of BAX for outcome prediction in gastrointestinal malignancies.

artículo científico

Role of cMET in the development and progression of colorectal cancer

artículo científico publicado en 2013

Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer

artículo científico publicado en 2011

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

artículo científico publicado en 2009

Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors.

artículo científico publicado en 1993

Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy

scientific article published on 04 September 2013

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

artículo científico publicado en 2015

TP53 mutations in advanced colorectal cancer: the dark side of the moon.

artículo científico

The luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers

artículo científico publicado en 2000

Treatment of carcinoid syndrome with recombinant interferon alpha-2a.

artículo científico publicado en 1993

Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase

artículo científico publicado en 2015

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

artículo científico publicado en 2007

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

artículo científico publicado en 2016

Lista de obras de Maria Di Bartolomeo

A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer

A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

Adjuvant chemotherapy for gastric cancer: current evidence and future challenges.

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

BRAF in metastatic colorectal cancer: the future starts now.

Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians.

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study11Data management by Italian Trials in Medical Oncology (I.T.M.O.) Scientific Service

Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies

Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab.

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology

Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials

Combined liver and pancreatic islets transplantation in man using cyclosporin immunosuppression

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients

Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer

Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens

Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours

Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma

Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group

FOLFIRI with cetuximab or bevacizumab: FIRE-3

FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma

Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.

Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer

Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials

Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer

Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

Pathological features as predictors of recurrence after radical resection of gastric cancer

Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases

Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases

Phase II Study of the Etoposide, Leucovorin and Fluorouracil Combination for Patients with Advanced Gastric Cancer Unsuitable for Aggressive Chemotherapy

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

Resection versus transplantation for liver metastases from neuroendocrine tumors

Role of BAX for outcome prediction in gastrointestinal malignancies.

Role of cMET in the development and progression of colorectal cancer

Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors.

Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

TP53 mutations in advanced colorectal cancer: the dark side of the moon.

The luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers

Treatment of carcinoid syndrome with recombinant interferon alpha-2a.

Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.